ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
Recruiting · NCT07504796 · Registry updated 2026-08-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, metastatic melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-08-24 | NCT07504796 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| NYU Langone Health | 359 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| NYU Langone Health | New York | United States | 403 |